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Background 
Soybean is considered an important allergenic food, but published data on soybean 
allergens are controversial. 
Objective 
We sought to identify relevant soybean allergens and correlate the IgE-binding 
pattern to clinical characteristics in European patients with confirmed soy allergy. 
Methods 
IgE-reactive proteins were identified from a soybean cDNA expression library, 
purified from natural soybean source, or expressed in Escherichia coli. The IgE 
reactivity in 30 sera from subjects with a positive double-blind, placebo-controlled 
soybean challenge (n = 25) or a convincing history of anaphylaxis to soy (n = 5) was 
analyzed by ELISA or CAP-FEIA. 
Results 
All subunits of Gly m 5 (β-conglycinin) and Gly m 6 (glycinin) were IgE-reactive: 53% 
(16/30) of the study subjects had specific IgE to at least 1 major storage protein, 43% 
(13/30) to Gly m 5 , and 36% (11/30) to Gly m 6. Gly m 5 was IgE-reactive in 5 of 5 
and Gly m 6 in 3 of 5 children. IgE-binding to Gly m 5 or Gly m 6 was found in 86% 
(6/7) subjects with anaphylaxis to soy and in 55% (6/11) of subjects with moderate 
but only 33% (4/12) of subjects with mild soy-related symptoms. The odds ratio (P < 
.05) for severe versus mild allergic reactions in subjects with specific IgE to Gly m 5 
or Gly m6 was 12/1. 
Conclusion 
Sensitization to the soybean allergens Gly m 5 or Gly m 6 is potentially indicative for 
severe allergic reactions to soy. 
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anaphylaxis; cDNA expression library 
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Soybean (Glycine max)–induced allergic symptoms may range from skin, 
gastrointestinal, or respiratory reactions to anaphylaxis.[1], [2] and [3] Food allergy to soy 
has been described primarily in young children with atopic dermatitis,[4], [5] and [6] but 
published data on the prevalence of soybean allergy in childhood are controversial. 
Moreover, the prevalence of soybean allergy in adults is still unknown.[7] and [8] 
Recently, we described the clinical characteristics of soybean allergy in 25 European 
adults and 5 children, in whom soy allergy was confirmed by a positive DBPCFC or 
according to a convincing history of anaphylaxis to soy.3 Cumulative threshold doses 
in soybean DBPCFC were at least 1 order of magnitude higher than observed in 
peanut allergy,[9] and [10] but no correlation was found between the level of threshold 
doses and the severity of symptoms. In addition, the pattern of IgE reactivity 
determined by immunoblotting was highly individual and apparently did not correlate 
with the severity of symptoms.3 To date, at least 16 IgE-binding soybean proteins 
have been described, of which several have been characterized in more detail: the 
soybean Kunitz trypsin inhibitor,[11], [12] and [13] the thiol-protease Gly m Bd 30k that has 
been suggested as a major soybean allergen,[14], [15] and [16] the α subunit of the major 
storage protein β-conglycinin (BC),17 the acidic chain of the major storage protein 
glycinin (G) G1 subunit,18 and the basic chain of the G2 subunit.19 Apart from a few 
exceptions, such as the work of Helm et al,[15], [16] and [19] most of the studies were 
based on subjects with atopic dermatitis whose food-related symptoms were not 
confirmed by DBPCFC. Moreover, IgE reactivity of the A5B3 glycinin was shown in 
children with cow's milk allergy but without confirmed soybean allergy.20 Finally, the 
putative soybean allergen 2S albumin13 showed no IgE-binding in 23 European 
subjects with soybean allergy.21 Interestingly, only the soybean hull proteins Gly m 1 
and Gly m 2 that are known as inhalant allergens in occupational or environmental 
soybean allergy as well as the birch pollen–related allergens Gly m 3 and Gly m 4 
have been accepted officially as soybean allergens by the International Union of 
Immunological Societies (IUIS) Allergen Nomenclature Sub-Committee 
(http://www.allergen.org/Allergen.aspx). Unlike the legume peanut with at least 8 
identified and officially accepted allergens, there is still a lack of knowledge on 
soybean allergens. The identification of relevant soybean allergens therefore remains 
an important task to achieve better understanding of the molecular mechanisms of 
soybean allergy with special regard to diagnosis, risk management, and future 
therapy. As an important step into this direction, we performed the identification of 2 
soybean allergens, Gly m 5 (β-conglycinin) and Gly m 6 (glycinin), using serum 
samples of 30 subjects with soybean allergy.3 The 2 soybean major storage proteins, 
β-conglycinin and glycinin, are 7 S and 11 S globulins and account for about 30% 
and 40% of the total seed proteins, respectively. In the vacuole, the mature form of β-
conglycinin is accumulated into the densely packed state as trimers that are 
composed of 3 subunits, α ( 67 kd), α′ ( 71 kd), and β ( 50 kd).22 Glycinin is 
synthesized in the seeds during embryogenesis. It is a hexameric protein that is 
assembled by 5 different subunits, G1 (A1aB1b, 53.6 kd), G2 (A2B1a, 52.4 kd), G3 
(A1bB2, 52.2 kd), G4 (A5A4B3, 61.2 kd), and G5 (A3B4, 55.4 kd). Each features at 
least 1 acidic (A) and basic (B) peptide chain that are linked by a disulfide bond.23 
Finally, the IgE reactivities to this complete panel of 8 subunits of the major storage 
proteins were correlated to the clinical characteristics of our patient group to 
investigate the potential use as biomarkers for severe allergic reactions to soybean. 
Methods 
Patients 
The patients were recruited in 3 European allergy centers—Zurich (Switzerland), 
Odense (Denmark), and Milan (Italy)—according to protocols approved by the Ethical 
Committees of the respective centers. The primary inclusion criterion was a positive 
food challenge (DBPCFC) with soy or a convincing history of anaphylactic reactions 
to soy. The clinical details of the study subjects have been published recently.3 
Challenges were discontinued after the dose leading to objective allergic symptoms 
or ingestion of the whole meal of 50 g soy ( 26.5 mg soy protein). The lowest 
observed adverse effect levels for subjective and for objective allergic reactions were 
5.3 mg and 240.6 mg of soy protein, respectively. The most relevant data necessary 
for interpretation of the in vitro results obtained in this study are summarized in Table 
I. To set uniform and comparable criteria for the depicted most severe symptom, 
symptoms were recorded as experienced under challenge. In addition, a convincing 
history of anaphylaxis, evaluated by a standardized case report form, was accepted. 
The severity of symptoms on soy ingestion was graded as follows: (1) mild: 
symptoms such as oral allergy syndrome (OAS), tightness of the throat, nausea, 
gastrointestinal pain, or dyspnea without monitored drop in FEV1; (2) moderate: 
symptoms such as rhinitis, flush, urticaria, angioedema, diarrhea, or emesis; and (3) 
severe: drop of blood pressure, or life-threatening laryngeal edema. 
Table I.  
Clinical characteristics of the study subjects with soybean allergy 
  Soybean allergy  CAP (kU/L) 
Patie
nt 
no. 
Age 
(y)/s
ex* 
Clinical 
evidenc
e 
Most severe 
symptom 
challenge/hi
story‡ 
Graded 
symptoms 
Peanut 
allergy 
accord
ing to 
history 
Soy 
extr
act 
So
y 
Gly 
m 4 
Pean
ut 
extra
ct 
1 31/M History Drop of blood Sever Objecti Yes 2.1 <0. 2.3 
  Soybean allergy  CAP (kU/L) 
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nt 
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(y)/s
ex* 
Clinical 
evidenc
e 
Most severe 
symptom 
challenge/hi
story‡ 
Graded 
symptoms 
Peanut 
allergy 
accord
ing to 
history 
Soy 
extr
act 
So
y 
Gly 
m 4 
Pean
ut 
extra
ct 
of 
anaphyl
axis to 
soy 
pressure e ve 35 
2 27/M 
Soybea
n 
DBPCF
C 
Rhinitis Moderate 
Objecti
ve Yes 
<0.3
5 3.2 
<0.3
5 
3 32/F 
Soybea
n 
DBPCF
C 
Drop of blood 
pressure 
Sever
e 
Objecti
ve Yes 0.5 4.0 0.8 
4 3/F 
Soybea
n 
DBPCF
C 
Angioedema, 
flush 
Moder
ate 
Objecti
ve No 
<0.3
5 3.1 
<0.3
5 
5 18/F 
Soybea
n 
DBPCF
C 
Urticaria Moderate 
Objecti
ve Yes 0.4 4.0 1.6 
6 22/F 
Soybea
n 
DBPCF
C† 
Angioedema Moderate 
Objecti
ve Yes 6.4 
<0.
35 >100 
7 17/F 
Soybea
n 
DBPCF
C 
OAS, 
tightness of 
throat 
Mild Subjective Yes 
<0.3
5 7.2 0.5 
8 9/M 
History 
of 
anaphyl
axis to 
soy 
Laryngeal 
edema 
Sever
e 
Objecti
ve Yes 15.9 
<0.
35 2.3 
9 40/F 
Soybea
n 
DBPCF
C 
Flush Moderate 
Objecti
ve No 
<0.3
5 1.0 
<0.3
5 
10 32/F Soybea Flush Moder Objecti Yes 1.6 9.3 4.7 
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4 1.1 
12 23/F 
Soybea
n 
DBPCF
C 
OAS, >20% 
decrease in 
FEV1 
Moder
ate 
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ve Yes 0.4 1.8 91.9 
13 39/F 
Soybea
n 
DBPCF
C 
OAS, nausea Mild Subjective No 
<0.3
5 0.4 
<0.3
5 
14 35/M 
Soybea
n 
DBPCF
C 
OAS, nausea Mild Subjective Yes 1.5 6.1 62.9 
15 22/F 
Soybea
n 
DBPCF
C 
OAS, nausea Mild Subjective Yes 1.3 
15.
4 3.2 
16 32/M 
Soybea
n 
DBPCF
C 
OAS Mild Subjective Yes 2.1 
77.
7 6.5 
17 18/M 
Soybea
n 
DBPCF
C 
OAS, nausea Mild Subjective No 1.8 
22.
8 5.3 
18 14/M 
Soybea
n 
DBPCF
C 
Diarrhea Moderate 
Objecti
ve Yes 10.0 4.1 21.1 
19 11/F 
Soybea
n 
DBPCF
OAS Mild Subjective No 20.8 
11.
2 19.0 
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20 6/M 
Soybea
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Emesis Moderate 
Objecti
ve No 4.7 
<0.
35 1.8 
21 9/F 
Soybea
n 
DBPCF
C 
OAS, GIT Mild Subjective Yes 18.1 
>10
0 >100 
22 44/F 
History 
of 
anaphyl
axis to 
soy 
Drop of blood 
pressure 
Sever
e 
Objecti
ve No 
<0.3
5 
17.
2 4.4 
23 16/F 
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Flush, 
urticaria 
Moder
ate 
Objecti
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<0.
35 7.4 
24 28/M 
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C 
OAS Mild Subjective Yes 3.1 
<0.
35 
<0.3
5 
25 69/F 
Soybea
n 
DBPCF
C 
Flush Moderate 
Objecti
ve No 
<0.3
5 
<0.
35 
<0.3
5 
26 44/F 
Soybea
n 
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GIT Mild Subjective Yes 0.7 6.3 5.8 
27 30/F 
History 
of 
anaphyl
axis to 
soy 
Drop of blood 
pressure 
Sever
e 
Objecti
ve Yes 2.9 
<0.
35 8.6 
28 24/M 
History 
of 
anaphyl
Drop of blood 
pressure 
Sever
e 
Objecti
ve Yes 52.5 0.6 >100 
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ut 
extra
ct 
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Soybea
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DBPCF
C 
GIT Mild Subjective No 1.2 2.4 1.5 
30 39/M 
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DBPCF
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Objecti
ve No 64.9 
<0.
35 20.6 
Full-size table 
Patients 1-18 and 28, Switzerland; patients 19-21, Denmark; patients 22-27, 29, and 
30, Italy. 
F, Female; GIT, gastrointestinal; M, male. 
* Age at time of blood drawing and challenge. 
† Challenge vehicle: chocolate drink instead of chocolate bar. 
‡ Most severe symptom in challenge or according to anaphylaxis history.  
 
SDS-PAGE and IgE immunoblot analysis 
SDS-PAGE was performed under reducing conditions, and IgE immunoblot analysis 
was performed as recently described.3 Soybean extract was subjected to SDS-PAGE 
at 20 μg/cm gel, purified natural BC was analyzed at 7.5 μg/cm with 2.5 μg/cm of 
each subunit (α, α′, and β), and recombinant proglycinin was analyzed at 10 μg/cm 
with each subunit (A1aB1b, A1bB2, A2B1a, A3B4, and A5A4B3) at 2 μg/cm. IgE 
reactivities were detected with horseradish peroxidase on polyclonal anti-IgE and 
visualized by chemiluminescence on x-ray–sensitive film. Alternatively, alkaline 
phosphatase (AP)–conjugated monoclonal anti-IgE (Pharmingen, San Diego, Calif; 
dilution 1:1000, 4 hours) and colorimetric staining with an AP-substrate solution (Bio-
Rad Laboratories, Hercules, Calif) were applied. Silver staining of gels was 
performed according to Heukeshoven and Dernick.24 
Establishment of a soybean cDNA expression library 
Total RNA was isolated from freeze-dried almost ripened but slightly green soybean 
seeds as previously described by Hoff et al.25 Five micrograms of poly(A) mRNA 
were purified from the isolated total RNA fraction by the Oligotex mRNA Midi Kit 
(Qiagen, Hilden, Germany). After reverse transcription and addition of EcoR I/Hind III 
linker arms, the cDNA was size-fractionated (Mini Column Fractionation Kit, 
Novagen, Madison, Wis) with fragments of as many as 3000 bases and a major 
portion of 1000 to 2000 bases in length. A cDNA expression library was established 
by using the λSCREEN-1 system (Novagen) according to the manufacturer's 
instructions (technical bulletin TB119 02/99). The most prominent cDNA fraction of 
approximately 300 to 2000 bases in length was directionally ligated into λSCREEN 
vector and in vitro packed. The primary library had a titer of 4.5 × 105 plaque-forming 
units per milliliter (pfu/mL; total library size, 2.25 × 105 pfu) and was amplified to 4 × 
109 pfu/mL. 
IgE screening of the soybean cDNA expression library 
For immunoscreening, 2 × 104 pfu was plated on 90-mm plates, incubated at 37°C 
until plaques appeared (5-7 hours), and overlaid with nitrocellulose filters (Hybond C; 
GE Healthcare, Munich, Germany; 4°C; overnight). The nitrocellulose plate lifts were 
blocked in 50 mmol/L TRIS-buffered saline (pH 7.4) containing 1% gelatin and 0.1% 
Tween 20 and incubated with patient serum no. 28 (diluted 1:10, overnight). The 
bound IgE was visualized with anti–IgE-AP as described. Nonspecific binding was 
reduced by serum preincubation with equal volumes of suspension and lysate of 
BL21(DE3)pLysE-plating cells. IgE-reactive phage recombinants were screened by 
PCR with SP6 promoter and T7 terminator primers. The purified PCR products were 
sequenced. 
Purification of natural BC subunits 
Soybean extract was prepared in 10 mmol/L PBS (pH 7.4) as recently described.3 
Natural α, α′, and β subunits of BC were purified from soybean extract by preparative 
SDS-PAGE (model 491 Prep-Cell; Bio-Rad Laboratories, Munich, Germany) as 
described by Reese et al.26 As much as 50 mg total protein from soybean extract was 
separated in the 28-mm internal diameter column with a 25-mm-high stacking gel 
(5% total acrylamide concentration; 1.5% cross-linker acrylamide concentration) and 
a 65-mm-high separation gel (7,5% T, 1.5% C). Fractions containing the purified 
single subunits were identified by IgE Western blotting, pooled, and dialyzed against 
3-(N-morpholino)-propanesulfonic acid buffer (20 mmol/L 3-(N-morpholino)-
propanesulfonic acid, 8 mmol/L sodium acetate, 1 mmol/L 2-(bis [carboxymethyl] 
amino) acetic acid, pH 7.0). The purity of the isolated BC subunits was checked by 
SDS-PAGE and silver staining, and purity and identity were verified by N-terminal 
sequencing and liquid chromatography tandem mass spectrometry. 
N-terminal sequencing and LC-MS/MS 
N-terminal sequencing analyses were performed on a Procise 492 protein sequencer 
(Applied Biosystems, Monza, Italy) after protein adsorption on ProSorb PVDF 
membranes (Applied Biosystems). For LC-MS/MS analyses, the spots cut from the 
gel were destained and the proteins trypsinized as described by Hellmann et al.27 
The tryptic mixtures were analyzed by LC-MS/MS as previously described.28 
Recombinant proglycinin subunits 
The recombinant proglycinin subunits G1 (A1aB1b, 53.6 kd), G2 (A2B1a, 52.4 kd), 
G3 (A1bB2, 52.2 kd), G4 (A5A4B3, 61.2 kd), and G5 (A3B4, 55.4 kd) were generated 
and purified as summarized elsewhere in detail.23 
ELISA for soybean-specific IgE 
Microtiter plates (Maxisorp F96, Nunc, Thermo Fisher Scientific, Langenselbold, 
Germany) were coated with either a mixture of 50 ng of each BC subunit or a mixture 
of 50 ng of each proglycinin subunit in 50 mmol/L carbonate buffer (pH 9.6) per well 
overnight. Human myeloma IgE (Biogenesis via AbD Serotec, Duesseldorf, 
Germany) was coated simultaneously to prepare a standard curve between 0.1 and 
218.7 ng IgE in a 3-fold dilution series. Excess binding sites were blocked with 2% 
BSA in 10 mmol/L PBS for 2 hours. Human sera, diluted at 1:4 in incubation buffer 
(10 mmol/L PBS containing 2% BSA and 0.05% Tween 20, pH 7.4) were added to 
wells coated with allergens (2 hours). Standard wells were incubated with incubation 
buffer only. Immunodetection was performed with biotin-conjugated antihuman IgE 
from goat (lot WJ 138; KPL Inc., Gaithersburg, Md) and horseradish peroxidase–
conjugated NeutrAvidin (Pierce, Rockford, Ill) each for 60 minutes (1:2000 and 
1:10,000, respectively). Enzymatic staining was performed with tetramethylbenzidine 
as described elsewhere.29 Plates were read at 450 nm (630 nm reference) 
wavelength and subtracted by the OD of the buffer blank. A semi-log sigmoidal IgE 
standard curve was fitted by the SOFTmax PRO software (version 2.4.1; Molecular 
Devices, Sunnyvale, Calif). Maximum ODs were calculated from asymptotal 
extrapolation to infinite concentration. The ODs of the soy allergic sera (0.05-2.8) as 
well as of a nonallergic serum pool (n = 3; OD 0.05) were calculated as percentage of 
the maximum OD (3.2) of the myeloma IgE to achieve comparability of the relative 
IgE-binding capacities between BC and proglycinin. The results were interpreted only 
in a qualitative manner: the IgE-binding to the soybean major storage proteins was 
considered positive if equal or greater than twice the reading of the nonallergic serum 
pool. 
Statistical analysis 
Statistical data analysis was performed using SAS/STAT software (SAS Institute Inc, 
Cary, NC). The odds ratios (ORs) were calculated within a 95% CI. Statistical 
significance was accepted at a probability value (Wald χ2) of P < .05. 
Results 
Screening of the cDNA expression library revealed IgE reactivity to various 
subunits of major soybean storage proteins 
For IgE immunoscreening of the soybean cDNA expression library, a representative 
soy-allergic serum had to be identified. A selection of sera showing an IgE-binding 
pattern that is representative for the soybean allergogram of the 30 study subjects3 is 
shown in Fig 1. In particular, the sera of patients 28 and 30 had very high levels of 
soybean-specific IgE and displayed a prominent IgE-binding over a broad range of 
molecular weight that covered the majority of IgE-binding soybean proteins (Fig 1). 
For a better comparability of the IgE-binding pattern of serum 28 with others, the 
resolution of immunodetection was improved while the sensitivity was decreased 
(lane 28*). Therewith, serum 28 was identified as a suitable candidate for 
immunoscreening. Furthermore, study subject 28 agreed on a separate blood 
donation to provide enough serum for IgE screening of the whole library. 
 
 Full-size image (23K) 
 
Fig 1. IgE-immunoblot analysis of a soybean extract. All lanes except for 28* and P 
were detected with peroxidase mediated chemiluminescence (lane C: buffer control; 
lane N: nonatopic control serum pool [n = 3]; lanes 1, 3, 14, 18, 21, 30, and 28: sera 
from subjects with soybean allergy summarized in Table I; lane 28*: patient 28 
detected with phosphatase and precipitating dye; lane P: silver-stained total soybean 
protein). 
 
For a primary screening of the entire soybean expression library, 20 plates with 2 × 
104 pfu/plate were immunodetected with serum 28. In total, 23 IgE-reactive primary 
clones were selected and underwent further rounds of enrichment and screening for 
IgE reactivity until pure clones of an IgE-reactive primary plaque were obtained. The 
cDNA sequences of positive clones were determined and translated amino acid 
sequences subjected to a Basic Local Alignment Search Tool search by using the 
algorithm of Altschul et al30 (status February 2007). The majority of IgE-reactive 
clones referred to cDNA of the major storage protein BC (see this article's Table E1 
in the Online Repository at www.jacionline.org). Expressed partial peptides of all 3 
subunits (α, α′, and β) were IgE-reactive. Of the storage protein glycinin, expressed 
fragments of 2 (G1, G2) of the 5 major subunits were IgE-reactive. The sequenced 
cDNA inserts ranged from 304 to 736 bp and encoded for partial sequences with 
approximately 15% (for the BC α′ subunit) and 54% (for the BC β subunit) of primary 
amino acid sequence coverage. 
A complete battery of highly purified natural β-conglycinin subunits and 
recombinant proglycinins from soybean 
All 3 subunits (α, α′, β) of the soybean major storage protein BC were purified from a 
natural soybean source. The proglycinins G1 to G5 were obtained by heterologous 
expression in Escherichia coli. All proteins featured high purity and convincing IgE-
binding characteristics. Details are given in this article's Figs E1 and E2 in the Online 
Repository at www.jacionline.org. 
IgE-binding to the soybean major storage proteins found in the majority of 
subjects with soybean allergy 
The frequency of sensitization to the soybean major storage proteins BC and G in our 
study population was analyzed by IgE-ELISA. β-Conglycinin, composed of the 3 
subunits α, α′, and β, and glycinin, composed of the proglycinins G1, G3, G4, and 
G5, were investigated in ELISA as either BC or G protein mixtures coupled to the 
solid phase. The G2 proglycinin was not included because of a low solubility in the 
coating buffer, resulting in precipitation of the protein. The results are given in Table 
II. The IgE ELISA proved to be adequately sensitive, because even in sera showing 
weak reactivity on immunoblots and in the CAP system, a clearly positive signal was 
obtained (eg, numbers 1, 2, 5, and 20). 
Table II.  
IgE reactivity of purified natural Gly m 5 and recombinant Gly m 6 in ELISA (N, 
nonatopic control serum pool) 
 
Gly m 5 (β-
conglycinin)  Gly m 6 (glycinin)  
Patient no. % OD IgE reactivity % OD IgE reactivity
1 6.7 + 29.8 + 
2 1.3  3.5 + 
 
Gly m 5 (β-
conglycinin)  Gly m 6 (glycinin)  
Patient no. % OD IgE reactivity % OD IgE reactivity
3 2.7 + 2.2  
4 1.2  1.8  
5 4.1 + 2.4  
6 4.1 + 83.0 + 
7 1.0  1.5  
8 63.6 + 3.1 + 
9 0.8  2.0  
10 1.3  2.3  
11 0.6  1.9  
12 1.1  6.1 + 
13 1.2  2.0  
14 24.7 + 17.0 + 
15 3.1 + 1.7  
16 1.1  1.6  
17 1.3  2.2  
18 10.8 + 1.7  
19 11.0 + 2.8 + 
20 2.4 + 1.6  
21 6.6 + 27.3 + 
22 0.7  2.2  
23 1.1  1.8  
24 1.7  1.5  
25 0.5  2.0  
26 1.4  2.6  
27 0.9  3.2 + 
28 69.8 + 87.8 + 
 
Gly m 5 (β-
conglycinin)  Gly m 6 (glycinin)  
Patient no. % OD IgE reactivity % OD IgE reactivity
29 1.0  1.7  
30 77.7 + 61.1 + 
N 1.0  1.4  
Cutoff 2.0  2.8  
±, Positive IgE binding equal to or greater than cutoff. 
 
Forty-three percent (13/30) of subjects had specific IgE to BC and 37% (11/30) to G. 
All of the 5 children (age ≤14 years) participating in the study (numbers 8, 18, 19, 20, 
and 21) had specific IgE to BC and 3 (60%) to G. In total, 53% (16/30) of the subjects 
with soybean allergy had specific IgE to 1 or more soybean major storage proteins. 
Thus, the official nomenclature was applied to BC (Gly m 5) and G (Gly m 6) by the 
IUIS Allergen Nomenclature Subcommittee. The subunits of the oligomeric allergens 
were designated as Gly m 5.0101 (α), Gly m 5.0201 (α′), Gly m 5.0301/Gly m5.0302 
(β), Gly m 6.0101 (G1), Gly m 6.0201 (G2), Gly m 6.0301 (G3), Gly m 6.0401 (G4), 
and Gly m 6.0501 (G5), following the rules for isoforms. 
Gly m 5 and Gly m 6 as potential diagnostic markers for severe allergic 
reactions to soybean 
According to the symptom classification, 12 (40%) subjects had mild allergic 
symptoms against soy, 11 (37%) had moderate reactions, and 7 (23%) had severe 
soy-related allergic reactions (Table I). Of those 7 subjects with severe soy-related 
allergic reactions, only 2 did not have a peanut allergy (according to history). Six of 7 
patients (86%) with anaphylaxis either by history or during soybean challenge 
(numbers 1, 3, 8, 22, 27, 28, and 30) were sensitized to Gly m 5 or Gly m 6. By 
contrast, only 4 of 12 (33%) subjects who experienced mild subjective symptoms 
(numbers 7, 11, 13-17, 19, 21, 24, 26, and 29) had specific IgE to the soybean major 
storage proteins. However, 11 (92%) of these subjects had IgE specific to the birch 
pollen–related soy allergen Gly m 4. 
Therefore, we calculated the ORs within a 95% CI in relation to the presence of 
specific serum IgE for the events “severe versus mild” and “severe versus moderate 
or mild” allergic reactions, respectively (Table III). Statistical significance with P < .05 
was given for the following events: we calculated an OR of 7.08 for the event of 
having a severe rather than a moderate or mild allergic reaction in the presence of 
IgE specific to proglycinin. Moreover, the event of rather having a severe than a mild 
soy-related allergic reaction was given an OR of 12.00 if specific IgE to Gly m 5 or 
Gly m 6 was detectable. By contrast, we calculated an OR of 0.07 (1/14) for the event 
of having a severe rather than a mild soy-related allergic reaction in those subjects 
with detectable Gly m 4 specific IgE. Interestingly, the presence and concentration of 
soybean specific serum IgE determined by CAP-FEIA did not give a statistically 
significant increase of the OR for both events, “severe versus mild” and “severe 
versus moderate or mild.” 
Table III.  
ORs for the events of severe versus mild, and severe versus moderate or mild 
allergic reactions, depending on the presence of soy allergen specific IgE 
Specific IgE Comparison OR P value
Gly m 5 Severe vs mild 5.00 .121 
(ELISA) Severe vs moderate/mild 4.69 .102 
Gly m 6 Severe vs mild 7.50 .060 
(ELISA) Severe vs moderate/mild 7.08 .042 
Gly m 5 or Severe vs mild 12.00 .049 
Gly m 6 (ELISA) Severe vs moderate/mild 7.80 .076 
Gly m 4 Severe vs mild 0.07 .038 
(CAP) Severe vs moderate/mild 0.21 .087 
Soy extract Severe vs mild 1.20 .891 
(CAP) Severe vs moderate/mild 2.12 .525 
 
Discussion 
Published data on soy allergens are still controversial, and no decision points of 
specific IgE for predicting clinical reactivity to soy were found.[3] and [4] To increase our 
knowledge on soy allergy at the molecular level and develop improved diagnostic 
tools for soy allergy, a directional cDNA expression library from developing soybean 
seeds was established. The library was screened with the serum of a subject with 
soybean allergy with a convincing history of anaphylaxis to soy and strong IgE 
reactivity to the majority of bands recognized by the other 29 sera of subjects with 
soy allergy. 
For the glycinins, heterologous expression of the 5 proglycinins appeared to be more 
straightforward than the purification of 6 acidic and 5 basic subunits from natural 
soybean source. By contrast, the 3 subunits of BC were easily accessible by 
purification in comparison with heterologous expression. Testing sera from our 
subjects with soybean allergy demonstrated for the first time IgE-binding to all 
subunits of BC (Gly m 5) and G (Gly m 6) (Figs E1 and E2). To our knowledge, this in 
vitro study on soybean allergens enrolls the largest number of clinically confirmed 
subjects with soybean allergy (n = 30) who were tested for IgE reactivity to a large 
panel of purified soybean allergens. In total, 53% (16/30) of the subjects with 
soybean allergy had specific IgE to 1 or more soybean major storage proteins, 
including 13 (43%) with specific IgE to Gly m 5 and 11 (36%) with IgE to Gly m 6. 
Neither Gly m 5 nor Gly m 6 was a major allergen in our study population according 
to the IUIS criteria. Also, the overall sensitivity of soybean CAP-FEIA in our patients 
with soybean allergy was 77% (23/30) and clearly below the already published 
sensitivity in children with soy allergy.4 Our study patients exhibited fairly low levels of 
soybean-specific IgE in CAP-FEIA, and of the 7 sera without specific IgE to soybean 
extract (< 0.35 kU/L), 6 showed IgE-binding to Gly m 4, the homolog to the birch 
pollen major allergen Bet v 1. These observations parallels the findings that in birch 
pollen–related soybean allergy mediated by Gly m 4, diagnosis is hampered by the 
fairly low levels of Gly m 4 in soybean extracts.2 
The depicted most severe symptoms were recorded as experienced under challenge. 
Subjects with a history of soy anaphylaxis were not challenged for ethical reasons. 
Because we did not want to miss the most severe reactors, a convincing history of 
anaphylaxis was accepted if approved by all clinical centers. Other symptoms 
according to case history were not considered to apply the most uniform criteria to 
evaluation of symptoms and subsequent correlation to allergen sensitization profiles. 
Interestingly, a sensitization to the storage proteins Gly m 5 and Gly m 6 was found in 
6 of 7 (86%) subjects with anaphylaxis either by history or occurrence during food 
challenge with soybean. Recently, the sensitizing and anaphylactic potential of the 
soybean major storage proteins was demonstrated in an animal model with BALB/c 
mice sensitized and challenged with purified natural Gly m 5 and Gly m 6.31 
By contrast, only 4 of 12 (33%) study subjects who experienced mild subjective 
symptoms had IgE specific for the soybean major storage proteins. However, 11 
(92%) of the subjects who experienced mild subjective symptoms had specific IgE to 
the birch pollen–related soy allergen Gly m 4. 
In our group of subjects with soybean allergy, we did not find any correlation between 
the level of specific IgE to soybean in CAP-FEIA and the severity of symptoms of 
soybean allergy.3 This finding is in full agreement with published data on soybean 
specific IgE levels in children and adolescents.[4] and [6] Moreover, the presence of 
specific serum IgE to soybean extract according to CAP-FEIA analysis did not give a 
statistically significant rise of the OR for the event of having a severe or moderate 
rather than a mild soy-related allergic reaction. However, by analyzing the IgE 
reactivity of our subjects with soybean allergy to soybean major storage proteins, a 
more distinct discrimination between mild and severe allergic reactions became 
evident. When calculating the ORs for the event of having a severe rather than a mild 
allergic reaction depending on the status of allergen sensitization, we found with 
statistical significance (P < .05) a high ratio (12/1) for those subjects with specific IgE 
to 1 or more of the soybean major storage proteins. By contrast, the OR for mild 
versus severe allergic reactions was 14 to 1 in subjects with sensitization to Gly m 4. 
Consequently, specific IgE to 1 or more soybean major storage proteins indicates a 
high risk of having a potentially severe allergic reaction to soy. 
Moreover, in the 5 children with soy allergy, we found a high frequency (>50%) of 
IgE-binding to Gly m 6 and especially to Gly m 5. Thus, the soybean major storage 
proteins are putative major soybean allergens in children. 
Two studies provided evidence that Gly m 4 is able to cause severe allergic reactions 
to soy in subjects with birch pollen allergy.[2] and [32] However, compared with the 
strong link to the soy storage proteins in the current study, this was not evident for 
Gly m 4. We believe that this may be explained by the fact that Kleine-Tebbe et al32 
investigated a population of subjects with birch pollen allergy preselected for severe 
reactions to soy. In the study by Mittag et al,2 a lower frequency of systemic reactions 
was observed, but evidence was provided that approximately 10% of subjects with 
birch pollen allergy with specific IgE of at least 17.5 kU/L to Bet v 1 are clinically 
allergic to soybean. It may still be premature to conduct a relative risk assessment of 
Gly m 4 versus the soy storage proteins. On one hand, the current study clearly 
shows a higher risk of serious reactions in patients IgE-positive to Gly m 5 or Gly m 6 
compared with Gly m 4, indicating a lower allergenicity per se of Gly m 4. On the 
other hand, this allergen can indeed induce severe reactions, in particular in patients 
with high IgE titers to Bet v 1, and on a population-based level, such patients may be 
far more numerous than Gly m 5±Gly m 6–positive subjects in central Europe. In this 
study about soybean allergens, soybean allergy of the underlying subjects was 
clinically confirmed in DBPCFC with soy-containing chocolate and chocolate drink, 
respectively. In these highly processed food matrixes, the heat-labile Gly m 4 may be 
denatured to a certain degree, thus facilitating less allergenic potential than the major 
soybean storage proteins. Finally, because case history was not included in grading 
symptom severity in challenged subjects, an underestimation of symptom severity 
cannot be fully excluded, in particular in those subjects with a predominant IgE 
reactivity to Gly m 4. 
In summary, we conclude from the current study that a sensitization to the soybean 
major storage proteins Gly m 5 or Gly m 6 is likely to result in severe reactions to 
soybean, and therefore, component-resolved in vitro testing with these molecules in 
purified form can provide a diagnostic marker to identify subjects with soy allergy who 
are at high risk for severe clinical symptoms. Nonetheless, in areas with birch trees, 
primary sensitization to Bet v 1 with potential clinical cross-reactivity to soybean Gly 
m 4, especially in soy products with a low processing level, still needs to be taken 
into account when assessing the risk for severe soybean-related allergic reactions. 
  
Clinical implications 
Component-resolved diagnosis with purified Gly m 5 and Gly m 6 is potentially 
applicable for identifying subjects at risk of experiencing severe soy-related allergic 
reactions. 
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Methods 
A complete battery of highly purified natural β-conglycinin subunits and 
recombinant proglycinins from soybean 
All 3 subunits (β, α, α′) of the major storage protein BC were purified from soybean 
extract by preparative SDS-PAGE, and the purity was verified by analytical SDS-
PAGE and silver staining (Fig E1, lanes β, α, and α′), LC-MS/MS, and N-terminal 
sequencing. The N-terminal sequences were identical to the mature subunits α 
(VEKEE), α′ (VEEEE), and β (LKVRE). The identity of natural β-conglycinin was 
further confirmed by nano-electrospray ionization MS/MS analysis followed by a 
MS/MS database search using Mascot. The amino acid sequence coverage obtained 
for the α, α′, and β subunits of natural purified BC was 35%, 37%, and 48%, 
respectively. The α (Gly m 5.0101) and α′ (Gly m 5.0201) subunits were identified 
referring to the database entries gi|9967357 and gi|9967361, respectively. The β 
subunit (Gly m 5.03) displayed 2 variants with 99.5% identity, refering to the 
database entries gi|21465630 (Gly m 5.0301) and gi|21465633 (Gly m 5.0302). 
All 3 subunits (Gly m 5.01, Gly m 5.02, and Gly m 5.03) were IgE-reactive in the 
immunoblot analysis of a mixture of the purified Gly m 5 subunits with selected 
patients' sera (Fig E1). Each of the subunits bound IgE from serum 28 when 
investigated as single protein (data not shown). Despite a broad range of IgE-reactive 
proteins in soybean extract (Fig 1) no other IgE-binding soybean proteins were 
present in the purified preparations of Gly m 5 subunits (Fig E1). 
The recombinant proglycinin subunits, A1aB1b (G1, 53.6 kd), A2B1a (G2, 52.4 kd), 
A1bB2 (G3, 52.2 kd), A5A4B3 (G4, 61.2 kd), and A3B4 (G5, 55.4 kd), were 
generated and purified as described elsewhere in detail.E1 Briefly, the host cells 
BL21-(DE3), HMS174(DE3), AD494(DE3), and Origami(DE3) containing the 
individual expression plasmids pEA1aB1b, pEA2B1a, pEA1bB2, pEA5A4B3, and 
pEA3B4 were cultured in lysogeny broth or terrific broth media to an optical density of 
0.6 at 600 nm wavelength, and overexpression was induced by addition of 1 mmol/L 
isopropyl-1-thio-β-D-galactosidase. Cells were lysed by sonification and the cell 
debris removed by centrifugation. An initial ammonium sulfate fractionation was 
achieved with ammonium sulfate saturation between 15% and 60%, depending on 
the subunit of interest. The prefractionated recombinant proglycinins underwent 
hydrophobic interaction chromatography and subsequently ion exchange 
chromatography (A1aB1b, A2B1a, A3B4) or a combination of gel filtration and ion 
exchange chromatography (A1bB2, A5A4B3). The recombinant proglycinins were 
kept at 4°C in PBS containing 400 mmol/L NaCl until used. The recombinant 
proglycinin subunits of soybean glycinin G1 to G5E1 each consisted of 1 single 
protein band at the anticipated molecular weight after total protein staining of the 
proteins (Fig E2, A, left). The IgE reactivity was verified with the highly sensitive 
serum 28 that reacted to each of the subunits Gly m 6.0101 (G1), Gly m 6.0201 (G2), 
Gly m 6.0301 (G3), Gly m 6.0401 (G4), and Gly m 6.0501 (G5). Also, some IgE-
binding proteins of lower molecular weight in the subunits G1, G3, and G4 were 
apparent, which might constitute spurious amounts of degradation products because 
the presence of other soybean proteins in the recombinant preparations can be 
excluded (Fig E2, A, right). Immunoblot analysis of a mixture of the 5 subunits of Gly 
m 6 with selected patients' sera having low to moderate levels of soybean specific 
IgE revealed IgE reactivity around the expected molecular weight with little or no IgE 
reactivity to potential breakdown products (Fig E2, B). Assignment of the IgE 
reactivities to the acidic or basic chains of the subunits was not possible because 
each of the recombinant proglycinins was composed of 1 peptide chain with the 
acidic chain fused to the basic chain. 
Because dissection of positive from negative results in immunoblot analyses turned 
out to be difficult for some sera, such as number 20 with Gly m 5 (Fig E1) and 
number 14 with Gly m 6 (Fig E2, B), an IgE-ELISA facilitating an objective cutoff 
proved to be more appropriate. By ELISA, the soybean major storage proteins were 
analyzed in a mixture representing the natural composition of these complex proteins 
better than the individual subunits. Gly m 5 and Gly m 6 were analyzed separately 
with the relevant subunits in an almost equimolar ratio. Only G2 (Gly m 6.02) was 
excluded from the mixture of Gly m 6 subunits because it precipitated in coating 
buffer. However, because of a high sequence similarity to G1 (83%) and G3 (85%), 
the exclusion of G2 from ELISA analysis was considered acceptable. 
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Fig E1.  
 
Purity testing of the individual Gly m 5 (β-conglycinin) subunits β (Gly m 5.03), α (Gly 
m 5.01), and α′ (Gly m 5.02) from natural soybean source in SDS-PAGE and silver 
staining (lanes β, α, and α′), and verification of the IgE reactivity of all Gly m 5 
subunits by immunoblot analysis with selected soy allergic sera (lane C: buffer 
control; N: nonatopic control serum pool [n = 3]; lanes 5, 14, 18, 19, and 20: subjects 
with soybean allergy).  
 
Fig E2.  
 
 A, Individual subunits of Gly m 6 by total protein staining of Western blots with 
Ponceau S (lanes: G1, Gly m 6.01, G2, Gly m 6.02; G3, Gly m 6.03; G4, Gly m 6.04; 
G5, Gly m 6.05) and verification of IgE-reactivity of all Gly m 6 subunits (double lane) 
with patient 28 (N: nonatopic serum pool). B, IgE immunoblot analysis of equal 
amounts (wt/wt) of the Gly m 6 subunits with selected patients' sera (lane C: buffer 
control; N: nonatopic control serum pool [n = 3]; lanes 1, 12, 14, 19, and 21: subjects 
with soybean allergy). The arrows indicate the position of the 5 proglycinin subunits 
according to molecular weight.  
 
Table E1.  
 
Identified IgE-reactive clones from the soybean cDNA expression library  
 Glycinin  β-Conglycinin  
 A1aBx  
 
A2B1a  α Subunit  α Prime  
 
β Subunit  
Alignment hit G1 (precursor) 
G2 
(precursor) (precursor)
subunit 
(precursor) (precursor)
GenBank acc. 
no. X02985 D00216 AB008678 AB008680 AB008679 
No. of primary 
IgE-reactive 
clones 
1 2 5 6 9 
Average size 
of insert (bp) 426 736 515 304 473 
Full-size table 
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